# An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D

> **NCT05210530** · PHASE1 · COMPLETED · sponsor: **CRISPR Therapeutics AG** · enrollment: 7 (actual)

## Conditions studied

- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Glucose Metabolism Disorders
- Metabolic Disease
- Endocrine System Diseases
- Autoimmune Diseases
- Immune System Diseases

## Interventions

- **COMBINATION_PRODUCT:** VCTX210A unit

## Key facts

- **NCT ID:** NCT05210530
- **Lead sponsor:** CRISPR Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-24
- **Primary completion:** 2023-01-19
- **Final completion:** 2023-01-19
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05210530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05210530, "An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05210530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*